1st Quarter - Report

COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

Firm
Client
Income
$140,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717).

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —

Contacted: SENATE

Bills named: H.R. 1717 (118th), S. 79 (118th)

Health Issues HCR

Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —
ANDREW DAVID LAZEROW —
ROBERT ALLEN LONG New —
JENNIFER L PLITSCH —
MICHAEL STERN —

Contacted: SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 142 (118th), S. 315 (118th), S. 574 (118th), S. 476 (118th), H.R. 1717 (118th), S. 79 (118th), S. 562 (118th), S. 4338 (118th), S. 150 (118th), H.R. 1790 (118th), S. 148 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.